News

The company has reported a net loss of $11.6m, or $0.24 loss per diluted share, compared to a net loss of $14.08m, or $0.30 loss per diluted share,

Valentine will succeed James Conway, who is retiring after 15 years as CEO at Netsmart. Prior to Netsmart, Valentine worked for Cerner Corporation as the executive vice president

The company has reported a net loss of $7.45m, or $0.07 loss per diluted share, compared to net loss of $10.34m or $0.10 loss per diluted share, for

The companies are expected to investigate the effects of the drug without a background of medical or surgical castration. Astellas and Medivation intend to recruit around 60 patients

rFIXFc is a recombinant Factor IX Fc fusion protein developed using monomeric Fc fusion technology. It is a clotting factor designed to replace the protein that hemophilia B

Under the agreement, Elan will receive $500m in cash and 31.9 million ordinary shares of Alkermes plc common stock. The combined company is expected to have growing product,

BAL30072 is a novel siderophore (iron-binding) sulfactam antibiotic conferring potent bactericidal activity against Gram-negative pathogens. NDM-1 is an enzyme that leads to resistance towards antibiotics that have been

The patented carrier can be tailored to small molecules, peptides, protein and nucleic acids-based drugs. The PolyPid platform can be utilized to address numerous medical indications in various

The company has reported a net loss of $2.6m, or $0.05 loss per diluted share, compared to net income of $44.34m or $1.22 per diluted share, for the